首页> 外文期刊>Case Reports in Nephrology and Dialysis >A Case of Frequently Relapsing Minimal-Change Nephrotic Syndrome with Steroid-Induced Psychiatric Syndrome Treated by Low-Dose, Short-Term Steroid Therapy in Combination with Cyclosporine
【24h】

A Case of Frequently Relapsing Minimal-Change Nephrotic Syndrome with Steroid-Induced Psychiatric Syndrome Treated by Low-Dose, Short-Term Steroid Therapy in Combination with Cyclosporine

机译:用低剂量诱导的类固醇诱导的精神病综合征频繁复发最小变化的肾病综合征,与环孢菌素联合治疗

获取原文
       

摘要

Adults with minimal-change nephrotic syndrome (MCNS) generally receive oral prednisolone (PSL) at an initial dosage of 1.0 mg/kg/day for a minimum of 4 weeks, with 80% of patients achieving clinical remission. However, relapses are frequent, necessitating repeated treatment with high-dose PSL. Long-term treatment with high-dose steroids increases the risk of steroid toxicities, such as diabetes mellitus, gastric complications, infections, osteoporosis, and steroid-induced psychiatric syndrome (SIPS), which may compromise the patient's quality of life. Strategies are therefore needed to reduce the dosage and duration of steroid therapy for frequently relapsing MCNS (FRNS). Here, we suggest a new combination therapy of low-dose and short-term steroid with cyclosporine (CsA). We encountered an adult patient who developed recurrence of FRNS with depression arising from SIPS and was treated using low-dose, short-term PSL combined with CsA. He was successfully treated with PSL at an initial dosage of 0.3 mg/kg/day (20 mg/day) for just 2 weeks combined with CsA, allowing earlier induction of complete remission. We then promptly reduced the dose of PSL to below a physiological dosage (5 mg/day) over 3 weeks without relapse after episodes of SIPS and quickly resolved psychiatric symptoms. CsA in combination with PSL can reduce the initial dosage of PSL, shorten the time to remission, and easily maintain clinical remission. This protocol appears clinically useful and potentially applicable as a future treatment strategy for FRNS troubled by SIPS.Copyright ? 2020 by S. Karger AG, Basel.
机译:具有最小变化的肾病综合征(MCN)的成年人通常在1.0mg / kg /天的初始剂量下接受口服泼尼松(PSL),至少4周,80%的患者实现临床缓解。然而,复发频繁,需要用高剂量PSL重复处理。具有高剂量类固醇的长期治疗增加了类固醇毒性的风险,例如糖尿病,胃并发症,感染,骨质疏松症和类固醇诱导的精神病综合征(啜饮),这可能会损害患者的生活质量。因此需要策略来减少类固醇治疗的剂量和持续时间,用于经常复发MCN(FRNS)。在这里,我们建议使用环孢菌素(CSA)的低剂量和短期类固醇的新组合治疗。我们遇到了一名成年患者,患有来自啜饮的抑郁症的复发,并使用低剂量进行治疗,与CSA联合使用的低剂量,短期PSL治疗。他以0.3mg / kg /天(20mg /天)的初始剂量成功用psl治疗,仅2周,结合CSA,允许早先诱导完全缓解。然后,我们在3周内迅速将PSL剂量减少到低于生理剂量(5毫克/天)而不会在啜饮发作后复发,并迅速解决精神症状。 CSA与PSL组合可以减少PSL的初始剂量,缩短缓解时间,易于维持临床缓解。该协议似乎临床上有用,并且可能适用于Sips.copyright令人困扰的FRNS的未来治疗策略? 2020由S. Karger AG,巴塞尔。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号